moxonidine has been researched along with Insulin Resistance in 21 studies
moxonidine: structure given in first source
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Serum insulin, glucose, C-reactive protein (CRP), lipids, uric acid, YKL-40 and blood pressure were measured and insulin sensitivity was calculated (HOMA) at the beginning and end of each study phase." | 9.14 | Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2010) |
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 9.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "Moxonidine is useful and safe for controlling arterial hypertension in obese patients." | 9.11 | Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. ( Abellán, J; de Vinuesa, SG; García-Galbis, JA; Hernández-Menárguez, F; Leal, M; Luño, J; Martínez-Pastor, A, 2005) |
| "To study whether insulin sensitivity and insulin response are altered by moxonidine treatment in obese patients with mild essential hypertension." | 9.09 | Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. ( Haenni, A; Lithell, H, 1999) |
| "A 6-month clinical study with active therapeutic intervention was carried out to evaluate the efficacy of moxonidine for the correction of arterial hypertension in 30 patients with metabolic syndrome." | 7.77 | Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome. ( Borodulina, EV; Gridneva, TD; Kseneva, SI; Kulakova, NV; Semiglazova, TA; Tarasova, IV; Trifonova, OJ; Udut, VV, 2011) |
| " In dose-response experiments, the maximal response (E(max)) was markedly reduced 18." | 5.34 | Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. ( Ernsberger, P; Sun, Z, 2007) |
| "The short-term effects of two sympatholytic antihypertensive drug treatments, β-blocking agent atenolol and imidazoline receptor-1 agonist moxonidine, on postmenopausal symptoms and their relationship to antihypertensive and insulin sensitivity effect were studied." | 5.19 | Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women. ( Kaaja, RJ; Kujala, SM; Pöyhönen-Alho, M, 2014) |
| " Serum insulin, glucose, C-reactive protein (CRP), lipids, uric acid, YKL-40 and blood pressure were measured and insulin sensitivity was calculated (HOMA) at the beginning and end of each study phase." | 5.14 | Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2010) |
| " We compared the effect of two sympatholytic antihypertensive drug treatments, the centrally acting imidazoline receptor-1 agonist moxonidine and peripherally acting beta-blocking agent atenolol on sensitive inflammatory markers in overweight postmenopausal women with diastolic hypertension." | 5.13 | Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women. ( Antikainen, RL; Ebeling, PE; Erkkola, RU; Kaaja, RJ; Katzman, P; Kibarskis, A; Manhem, K; Pöyhönen-Alho, MK; Tuomilehto, JO, 2008) |
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 5.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "Moxonidine is useful and safe for controlling arterial hypertension in obese patients." | 5.11 | Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. ( Abellán, J; de Vinuesa, SG; García-Galbis, JA; Hernández-Menárguez, F; Leal, M; Luño, J; Martínez-Pastor, A, 2005) |
| "To study whether insulin sensitivity and insulin response are altered by moxonidine treatment in obese patients with mild essential hypertension." | 5.09 | Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. ( Haenni, A; Lithell, H, 1999) |
| "The I1-imidazoline receptor is a specific high-affinity binding site corresponding to a functional cell-surface receptor mediating the antihypertensive actions of moxonidine and other second-generation centrally-acting agents, and may play a role in countering insulin resistance in an animal model of metabolic syndrome X." | 4.79 | The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. ( Ernsberger, P; Friedman, JE; Koletsky, RJ, 1997) |
| "A 6-month clinical study with active therapeutic intervention was carried out to evaluate the efficacy of moxonidine for the correction of arterial hypertension in 30 patients with metabolic syndrome." | 3.77 | Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome. ( Borodulina, EV; Gridneva, TD; Kseneva, SI; Kulakova, NV; Semiglazova, TA; Tarasova, IV; Trifonova, OJ; Udut, VV, 2011) |
| "The sympatholytic antihypertensive agent moxonidine, a centrally acting selective I1-imidazoline receptor modulator (putative agonist), may be beneficial in hypertensive patients with insulin resistance." | 3.69 | Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. ( Fogt, DL; Gödicke, J; Henriksen, EJ; Jacob, S; Youngblood, EB, 1997) |
| "Moxonidine has unique effects on a number of cell types through this unusual cellular site of action." | 2.48 | Pharmacological properties of the central antihypertensive agent, moxonidine. ( Brown-Bryan, TA; Edwards, LP; Ernsberger, P; McLean, L, 2012) |
| "It is urgent to treat hypertension in these patients with drugs that do not further impair glucose control." | 2.40 | Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. ( Lithell, HO, 1997) |
| "Moxonidine has been shown to improve glucose tolerance in man, probably by two different mechanisms, i." | 2.40 | Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. ( Hansson, L, 1998) |
| " In dose-response experiments, the maximal response (E(max)) was markedly reduced 18." | 1.34 | Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. ( Ernsberger, P; Sun, Z, 2007) |
| "Moxonidine treatment enhanced the expression of IRS-1 protein in skeletal muscle by 74% in SHROB and 40% in SHR." | 1.30 | Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. ( Bedol, D; Ernsberger, P; Farrell, CJ; Friedman, JE; Ishizuka, T; Koletsky, RJ; Liu, S, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (47.62) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kujala, SM | 1 |
| Pöyhönen-Alho, M | 1 |
| Kaaja, RJ | 2 |
| Hausberg, M | 1 |
| Hillebrand, U | 1 |
| Kisters, K | 1 |
| Pöyhönen-Alho, MK | 1 |
| Manhem, K | 2 |
| Katzman, P | 2 |
| Kibarskis, A | 2 |
| Antikainen, RL | 1 |
| Erkkola, RU | 1 |
| Tuomilehto, JO | 1 |
| Ebeling, PE | 1 |
| Masajtis-Zagajewska, A | 1 |
| Majer, J | 1 |
| Nowicki, M | 1 |
| Edwards, LP | 1 |
| Brown-Bryan, TA | 1 |
| McLean, L | 1 |
| Ernsberger, P | 5 |
| Kseneva, SI | 1 |
| Borodulina, EV | 1 |
| Semiglazova, TA | 1 |
| Kulakova, NV | 1 |
| Tarasova, IV | 1 |
| Trifonova, OJ | 1 |
| Gridneva, TD | 1 |
| Udut, VV | 1 |
| Rayner, B | 1 |
| Abellán, J | 1 |
| Leal, M | 1 |
| Hernández-Menárguez, F | 1 |
| García-Galbis, JA | 1 |
| Martínez-Pastor, A | 1 |
| de Vinuesa, SG | 1 |
| Luño, J | 1 |
| Chazova, I | 1 |
| Almazov, VA | 1 |
| Shlyakhto, E | 1 |
| Sun, Z | 1 |
| Kaaja, R | 1 |
| Kujala, S | 1 |
| Antikainen, R | 1 |
| Ylihärsilä, H | 1 |
| Erkkola, R | 1 |
| Tuomilehto, J | 1 |
| Friedman, JE | 3 |
| Koletsky, RJ | 3 |
| Lithell, HO | 1 |
| Henriksen, EJ | 1 |
| Jacob, S | 1 |
| Fogt, DL | 1 |
| Youngblood, EB | 1 |
| Gödicke, J | 1 |
| Krentz, AJ | 1 |
| Evans, AJ | 1 |
| Hansson, L | 1 |
| Ishizuka, T | 1 |
| Liu, S | 1 |
| Farrell, CJ | 1 |
| Bedol, D | 1 |
| Haenni, A | 1 |
| Lithell, H | 1 |
| Schachter, M | 1 |
6 reviews available for moxonidine and Insulin Resistance
| Article | Year |
|---|---|
Pharmacological properties of the central antihypertensive agent, moxonidine.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Central Nervous System; Heart Failure; Humans; Hyp | 2012 |
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Cardiovascular Dis | 2004 |
The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
Topics: Animals; Antihypertensive Agents; Binding Sites; Clonidine; Humans; Hypertension; Imidazoles; Imidaz | 1997 |
Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Humans; Hypertension; Imidazoles; Imidazoline | 1997 |
Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives.
Topics: Antihypertensive Agents; Humans; Hyperlipidemias; Hypertension; Imidazoles; Insulin Resistance; Obes | 1998 |
Metabolic effects of moxonidine and other centrally acting antihypertensives.
Topics: Animals; Antihypertensive Agents; Diabetes Complications; Humans; Hypertension; Imidazoles; Insulin | 1999 |
7 trials available for moxonidine and Insulin Resistance
| Article | Year |
|---|---|
Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women.
Topics: Atenolol; Blood Pressure; Body Mass Index; Double-Blind Method; Drug Monitoring; Female; Hot Flashes | 2014 |
Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women.
Topics: Adiponectin; Antihypertensive Agents; Atenolol; C-Reactive Protein; Double-Blind Method; Female; Fin | 2008 |
Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
Topics: Adipokines; Adult; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Body Size; Chiti | 2010 |
Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Diabetes Mellit | 2005 |
Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; G | 2006 |
Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Finland | 2007 |
Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 1999 |
8 other studies available for moxonidine and Insulin Resistance
| Article | Year |
|---|---|
Addressing the relationship between sympathetic activity and inflammation.
Topics: Antihypertensive Agents; Atenolol; C-Reactive Protein; Female; Humans; Hypertension; Imidazoles; Inf | 2008 |
Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome.
Topics: Adrenocorticotropic Hormone; Antihypertensive Agents; Female; Humans; Hydrocortisone; Hypertension; | 2011 |
Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine.
Topics: Adipocytes; Animals; Dose-Response Relationship, Drug; Female; Glucose; Hypertension; Imidazoles; In | 2007 |
Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats.
Topics: Animals; Antihypertensive Agents; Biological Transport; Blood Glucose; Body Weight; Fatty Acids, Non | 1997 |
Selective imidazoline receptor agonists for metabolic syndrome.
Topics: Antihypertensive Agents; Humans; Hypertension; Imidazoles; Imidazoline Receptors; Insulin Resistance | 1998 |
[The significance of the sympathetic nervous system during therapy for hypertension and related pathologies. Imidazoline-I1-receptor agonists. 17th Scientific Meeting of the International Society of Hypertension. Amsterdam, June 7, 1998].
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Humans; Hypertension; Imidazoles; Imidazoline Re | 1998 |
Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Female; Hyperglycemia; Hypertension; Hypog | 1998 |
Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X.
Topics: Animals; Anti-Obesity Agents; Carrier Proteins; Disease Models, Animal; Endocrine System; Female; Hy | 1999 |